Furthermore, KDM5A expression is implicated in drug resistance to targeted anti-cancer therapies in both lung [23] and breast cancer [15], as well as in resistance to a DNA alkylating agent in glioblastoma [24]. The gene discussed is KDM5A; the disease is breast carcinoma.